<?xml version="1.0" encoding="UTF-8"?>
<ref id="ppat.1007601.ref015">
 <label>15</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Wilhelm</surname>
   <given-names>SM</given-names>
  </name>, 
  <name>
   <surname>Dumas</surname>
   <given-names>J</given-names>
  </name>, 
  <name>
   <surname>Adnane</surname>
   <given-names>L</given-names>
  </name>, 
  <name>
   <surname>Lynch</surname>
   <given-names>M</given-names>
  </name>, 
  <name>
   <surname>Carter</surname>
   <given-names>CA</given-names>
  </name>, 
  <name>
   <surname>Schutz</surname>
   <given-names>G</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Regorafenib (BAY 73–4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity</article-title>. 
  <source>Int J Cancer</source>. 
  <year>2011</year>;
  <volume>129</volume>(
  <issue>1</issue>):
  <fpage>245</fpage>–
  <lpage>55</lpage>. Epub 2010/12/21. 
  <pub-id pub-id-type="doi">10.1002/ijc.25864</pub-id> .
  <?supplied-pmid 21170960?>
  <pub-id pub-id-type="pmid">21170960</pub-id>
 </mixed-citation>
</ref>
